This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
AEterna Zentaris, Inc.
Drug Names(s): KRX-0401, YHI-1003
Description: Perifosine is a novel, oral anticancer treatment that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway. Perifosine works by interfering with membranes of cancer cells thereby inhibiting Akt signaling which then affects cell death, growth, differentiation and survival. Perifosine, in combination with chemotherapeutic agents, is currently being studied for the treatment of colorectal cancer, multiple myeloma and other cancers, and is the most advanced anticancer agent of its class. Perifosine, as monotherapy, is being explored in other indications.
ACCESS Oncology and Zentaris AG
In September 2002, ACCESS Oncology (which includes subsidiary, AOI Pharma), which Keryx acquired in February 2004, enteredinto an exclusive commercial license agreement with Zentaris AG to acquire aseries of U.S. and foreign patents and patent applications relating to thecomposition of matter and use of Perifosine in the treatment of cancer and otherconditions. This license agreement covers the United States, Canada and Mexico.
Aeterna Zentaris and Yakult Honsha
In March 2011, Aeterna Zentaris and Yakult Honsha announced the signing of an exclusive development, commercialization and licensing agreement for the development, registration and marketing of perifosine in Japan. Under the terms of the agreement, Aeterna Zentaris will receive an initial 6 million Euro (US$ 8.3 M) upfront payment and will be entitled to receive additional up to 44 million Euro (US$ 60.9 M) payments upon achieving certain pre-established milestones...See full deal structure in Biomedtracker
Partners: Yakult Honsha Co. Ltd. Keryx Biopharmaceuticals Inc.
Additional information available to subscribers only: